Alligator Bioscience AB (publ) (ATORX.ST)
SEK 0.27
(-3.79%)
SEK 0.27
(-3.79%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -248.98 Million SEK | -31.12% |
| 2022 | -192.78 Million SEK | -36.18% |
| 2021 | -141.56 Million SEK | 1.89% |
| 2020 | -144.29 Million SEK | 32.73% |
| 2019 | -214.51 Million SEK | -40.14% |
| 2018 | -153.08 Million SEK | -145.72% |
| 2017 | -62.29 Million SEK | -11.09% |
| 2016 | -56.08 Million SEK | -127.63% |
| 2015 | 203 Million SEK | 362.92% |
| 2014 | -77.21 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -47.69 Million SEK | 20.7% |
| 2024 Q3 | -62.03 Million SEK | -30.06% |
| 2024 Q1 | -60.14 Million SEK | 15.94% |
| 2023 Q3 | -52.72 Million SEK | 17.22% |
| 2023 Q2 | -63.68 Million SEK | -2.4% |
| 2023 FY | -252.77 Million SEK | -31.12% |
| 2023 Q1 | -62.19 Million SEK | -18.55% |
| 2023 Q4 | -71.55 Million SEK | -35.72% |
| 2022 Q1 | -43.02 Million SEK | -16.68% |
| 2022 FY | -192.78 Million SEK | -36.18% |
| 2022 Q4 | -52.45 Million SEK | -2.02% |
| 2022 Q3 | -51.41 Million SEK | -12.05% |
| 2022 Q2 | -45.88 Million SEK | -6.66% |
| 2021 FY | -141.56 Million SEK | 1.89% |
| 2021 Q2 | -34.49 Million SEK | -6.06% |
| 2021 Q3 | -37.67 Million SEK | -9.24% |
| 2021 Q4 | -36.87 Million SEK | 2.14% |
| 2021 Q1 | -32.52 Million SEK | 4.64% |
| 2020 Q2 | -34.7 Million SEK | 22.62% |
| 2020 Q3 | -30.63 Million SEK | 11.74% |
| 2020 FY | -144.29 Million SEK | 32.73% |
| 2020 Q4 | -34.1 Million SEK | -11.33% |
| 2020 Q1 | -44.85 Million SEK | 24.37% |
| 2019 Q2 | -50.5 Million SEK | -9.23% |
| 2019 FY | -214.51 Million SEK | -40.14% |
| 2019 Q4 | -59.3 Million SEK | -1.44% |
| 2019 Q3 | -58.46 Million SEK | -15.76% |
| 2019 Q1 | -46.23 Million SEK | -53.82% |
| 2018 Q3 | -39.91 Million SEK | -2.07% |
| 2018 Q4 | -30.06 Million SEK | 24.7% |
| 2018 Q1 | -43.99 Million SEK | -509.89% |
| 2018 FY | -153.08 Million SEK | -145.72% |
| 2018 Q2 | -39.1 Million SEK | 11.11% |
| 2017 Q3 | -24.45 Million SEK | 16.95% |
| 2017 FY | -62.29 Million SEK | -11.09% |
| 2017 Q1 | -19.12 Million SEK | 13.6% |
| 2017 Q2 | -29.45 Million SEK | -54.03% |
| 2017 Q4 | 10.73 Million SEK | 143.88% |
| 2016 Q2 | -47.67 Million SEK | -297.91% |
| 2016 Q1 | 24.09 Million SEK | 161.59% |
| 2016 FY | -56.08 Million SEK | -127.63% |
| 2016 Q4 | -22.13 Million SEK | -142.36% |
| 2016 Q3 | -9.13 Million SEK | 80.85% |
| 2015 FY | 203 Million SEK | 362.92% |
| 2015 Q3 | 274.32 Million SEK | 0.0% |
| 2015 Q4 | -39.11 Million SEK | -114.26% |
| 2014 FY | -77.21 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Ziccum AB (publ) | -21.56 Million SEK | -1054.838% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -1418.096% |
| BioArctic AB (publ) | 252.64 Million SEK | 198.552% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -29365.444% |
| Mendus AB (publ) | -100.65 Million SEK | -147.375% |
| Genovis AB (publ.) | 54.22 Million SEK | 559.175% |
| Intervacc AB (publ) | -93.57 Million SEK | -166.067% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -1505.099% |
| Active Biotech AB (publ) | -46.48 Million SEK | -435.632% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 1482.548% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -349.29% |
| Aptahem AB (publ) | -10.1 Million SEK | -2364.017% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 22.557% |
| Kancera AB (publ) | -65.04 Million SEK | -282.803% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -84.957% |
| Fluicell AB (publ) | -26.87 Million SEK | -826.311% |
| Saniona AB (publ) | -81.06 Million SEK | -207.14% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -1912.634% |
| Biovica International AB (publ) | -126.07 Million SEK | -97.491% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -485.773% |
| AcouSort AB (publ) | -17.48 Million SEK | -1323.818% |
| Xintela AB (publ) | -57.23 Million SEK | -334.996% |
| Abliva AB (publ) | -96.54 Million SEK | -157.885% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 23.343% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -7003.652% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1465.734% |
| Amniotics AB (publ) | -29.07 Million SEK | -756.406% |
| 2cureX AB (publ) | -36.36 Million SEK | -584.715% |
| CombiGene AB (publ) | -36.3 Million SEK | -585.806% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -1600.704% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 35.228% |
| Camurus AB (publ) | 532.35 Million SEK | 146.77% |
| Corline Biomedical AB | -1.78 Million SEK | -13825.224% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -37.739% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -497.325% |
| I-Tech AB | 24.43 Million SEK | 1118.961% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 68.423% |
| Cyxone AB (publ) | -21.66 Million SEK | -1049.453% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -134.967% |
| Biosergen AB | -27.26 Million SEK | -813.196% |
| Cantargia AB (publ) | -290.01 Million SEK | 14.149% |
| NextCell Pharma AB | -43.17 Million SEK | -476.722% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -37.739% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -1356.358% |
| Nanologica AB (publ) | -69.96 Million SEK | -255.878% |
| SynAct Pharma AB | -224.49 Million SEK | -10.908% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -463.616% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -939.41% |
| LIDDS AB (publ) | -40.67 Million SEK | -512.143% |
| Lipum AB (publ) | -37.25 Million SEK | -568.339% |
| BioInvent International AB (publ) | -369.94 Million SEK | 32.697% |
| Alzinova AB (publ) | -16.52 Million SEK | -1406.979% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 1.761% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -3794.467% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -116.37% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -1136.323% |
| Simris Alg AB (publ) | -36.63 Million SEK | -579.631% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -69.877% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 19.793% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -124.483% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -2052.715% |